Comparing two dialysis filters for sepsis patients
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a newer, higher-performing dialysis filter helps people with kidney failure and sepsis better than the standard filter. It focuses on patients with high levels of inflammation (measured by a marker called interleukin-6).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have end-stage kidney disease and be on hemodialysis.
- You must have sepsis (a serious infection affecting your whole body).
- Your blood level of interleukin-6 (a marker of inflammation) must be higher than 50 pg/ml.
- You cannot need a different type of dialysis called continuous kidney replacement therapy.
- You cannot be pregnant or expected to pass away within 24 hours.
- You cannot have had an allergic reaction to the dialysis filters used in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of dialysis filter (oXiris) helps reduce blood clotting problems in patients with septic shock and kidney failure. It may offer a better option for those needing kidney support in the ICU.
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This trial tests a special blood filter called Oxiris that may help remove toxins and inflammation from the blood in patients with septic shock. It aims to see if this treatment can improve outcomes for people who need kidney replacement therapy.
This study compares two blood-thinning drugs (nafamostat and heparin) that are given during dialysis for kidney failure caused by sepsis. The goal is to see which drug is safer and helps keep the dialysis filter working better.
This study looks back at how a special kidney filter called oXiris helped patients in the ICU who had septic shock (a life-threatening blood infection) and kidney failure. Researchers want to understand if this filter improved survival and recovery compared to standard treatment.
Hear when a new End Stage Kidney Disease (ESRD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.